Research programme: multiple myeloma therapeutics - Shenzhen Ionova Life Sciences
Alternative Names: Programme CLatest Information Update: 28 Sep 2024
At a glance
- Originator Shenzhen Ionova Life Sciences Co., Ltd.
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Multiple-myeloma in China
- 21 Aug 2020 Early research in Multiple myeloma in China (unspecified route) (Shenzhen Ionova Life Sciences pipeline August 2020)